Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI503 combinations in advanced cancer
NCT02483247Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Sep 2015
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of amcasertib in solid tumor (advanced stage) (6 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Dose-Limiting Toxicities at 4 weeks and Recommended Phase 2 Dose at 4 weeks. Started Sep 2015; status: completed.
02
Drugs
amcasertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02483247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02483247.